NYSEMKT: MLSSMilestone Scientific Inc Stock
$0.56+0.02 (+3.7%)
Updated Apr 23, 2024
MLSS Price
$0.56
Fair Value Price
N/A
Market Cap
$42.67M
52 Week Low
$0.52
52 Week High
$1.35
P/E
-5.57x
P/B
5.33x
P/S
5.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.83M
Earnings
-$6.93M
Gross Margin
69.1%
Operating Margin
-71.79%
Profit Margin
-70.5%
Debt to Equity
0.42
Operating Cash Flow
-$5M
Beta
0.94
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MLSS Overview
Milestone Scientific, Inc. is a biomedical technology research and development company. The company is headquartered in Livingston, New Jersey and currently employs 16 full-time employees. The firm uses its CompuFlo technology for the delivery of medicaments. The CompuFlo pressure or force Computer-Controlled Local Anesthetic Delivery (C-CLAD) technology is a medical technology for the delivery of drugs, anesthetics and other medicaments into various tissue types. Milestone's product portfolio includes Single Tooth Anesthesia Instrument (STA Instrument), CompuDent, CompuMed and The Wand. The firm's STA Instrument is a computer-controlled local anesthesia delivery instrument that utilizes the pressure feedback elements of Milestone's CompuFlo technology. CompuDent (also known as the Wand Plus internationally) is Milestone's C-CLAD instrument. CompuMed is a computer-controlled injection instrument offered by the Company. The Wand handpiece is used in conjunction with the STA, CompuDent and CompuMed instruments.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MLSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MLSS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MLSS is poor value based on its book value relative to its share price (5.33x), compared to the US Medical Instruments & Supplies industry average (3.54x)
P/B vs Industry Valuation
MLSS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MLSS due diligence checks available for Premium users.
Be the first to know about important MLSS news, forecast changes, insider trades & much more!
MLSS News
Valuation
MLSS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.57x
Industry
48.7x
Market
41.92x
MLSS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.33x
Industry
3.54x
MLSS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MLSS's financial health
Profit margin
Revenue
$2.3M
Net Income
-$1.9M
Profit Margin
-85.8%
MLSS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MLSS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.4M
Liabilities
$3.4M
Debt to equity
0.42
MLSS's short-term assets ($10.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MLSS's short-term assets ($10.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MLSS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MLSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$514.3k
Financing
$2.6M
MLSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MLSS vs Medical Stocks
Milestone Scientific Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.